Figure_1.tif (1.16 MB)

Overview of the RAE workflow.

Download (0 kB)
figure
posted on 11.09.2008 by Barry S. Taylor, Jordi Barretina, Nicholas D. Socci, Penelope DeCarolis, Marc Ladanyi, Matthew Meyerson, Samuel Singer, Chris Sander

Input is a set of patients; tumor DNA, (un) matched non-tumor DNA, and an unrelated reference normal cohort. Tumor and non-tumor samples are quantified, normalized, and subject to quality control. In the assessment phase, individual samples are segmented and a multi-component model is parameterized for each; this produces a detector for single-copy gain, amplification, hemizygous loss, and homozygous deletion. Across all tumors, a unified breakpoint profile (UBP) is derived from the ensemble of segmentation breakpoints, and each region is scored for gain and loss. A background model of random aberrations is constructed with supplemental cleavage and permutation of genomic regions, and p-values are assigned and corrected for multiple hypothesis testing. In the output phase, RAE determines genomic boundaries for regions of interest (ROI), controls for germline and population copy-number variation, and reports statistically significant alterations.

History

Licence

Exports

Read the peer-reviewed publication

Logo branding

Keyword(s)

Licence

Exports